​

Year Ended December 31,

(In thousands, except share and per share data)

  ​ ​ ​

2025

  ​ ​ ​

2024

  ​ ​ ​

2023

Numerator:

​

​

  ​

  ​ ​ ​

​

​

​

​

​

Net loss attributable to CASI Pharmaceuticals, Inc.

​

$

(48,058)

​

$

(39,258)

​

$

(26,960)

Denominator:

​

  ​

​

​

  ​

​

​

​

Weighted-average shares outstanding used in computing net loss per share, basic and diluted

​

18,538,046

​

15,340,277

​

13,360,185

Denominator for basic and diluted net loss per share calculation

​

18,538,046

​

15,340,277

​

13,360,185

Net loss per share

​

  ​

​

​

  ​

​

​

​

— Basic and diluted

​

$

(2.59)

​

$

(2.56)

​

$

(2.02)